In this study, we characterized the expression of TAAs on PDAC cell lines and patient tumor samples and tested the efficacy of IgA mAbs directed against these TAAs, to investigate whether IgA mAbs in combination with CD47 blockade could pose a promising therapeutic strategy for PDAC. The gene discussed is CD79A; the disease is neoplasm.